Phase 2 N=18 Early Insulin and Development of ARDS
Respiratory Distress Syndrome, Adult · Sepsis · Hyperglycemia
Primary: Plasma Levels of Free Fatty Acids, Tumor Necrosis Factor-α, Interleukin-6, and Von Willebrand Factor Antigen
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=513 Linking Endotypes and Outcomes in Pediatric Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome
Primary: 28 Day Mortality in Pediatric ARDS. — 44 Participants — p=<0.05
Phase 1 N=9 Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome
Primary: Incidence of Pre-specified Infusion Associated Adverse Events — 0; 0; 0 participants
Phase 2 N=120 Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome
Respiratory Distress Syndrome, Adult
Primary: Change in Oxygenation Index (OI) — -0.7; -1.5; 0.8; -1.1 cmH20/mmHg — p=0.34
Phase 2 N=66 Add-on Reparixin in Adult Patients With ARDS
Acute Respiratory Distress Syndrome, Adult
Primary: Change in Oxygenation Index (OI) From Baseline to Day 7 of Treatment — -5.3; -6.6 Index — p=0.735
Phase 2 N=6 Extracorporeal Membrane Oxygenation (ECMO) in Non-intubated Patients With Acute Respiratory Distress Syndrome (ARDS)
ARDS
Primary: Number of Participants That Did Not Require Endotrachael Intubation — 3 participants
N/A N=13 Electrical Impedance Tomography (EIT) Monitoring in Adults With ALI or ARDS
Acute Lung Injury (ALI) · ARDS
Primary: Feasibility of EIT Monitoring in This Population of ARDS/ALI Patients — 13 Patients successfully monitored with EIT
Phase 3 N=52 Nitric Oxide Administration for Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome
Primary: Mean PaO2/FiO2 Ratio — 115.6; 115.9 mmHg — p=>0.05
Phase 2 N=77 SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Lung Injury, Acute
Primary: Mean Hematology Parameters Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, White Blood Cell Count — 0.0305; 0.0163; 0.0208; 0.0153…
Phase 2 N=60 Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)
Respiratory Distress Syndrome, Adult
Primary: Numbers of Patients Occurred Pre-specified Infusion Associated Events Occurring Within 6 Hours of Study Infusion — 0; 0 Participants
N/A N=139 The Role of Circulating Soluble CD74 in Acute Lung Injury
Acute Lung Injury · Acute Respiratory Distress Syndrome
Primary: Number of Participants Receiving Mechanical Ventilation — 51; NA participants
Phase 2 N=132 A Randomized Trial of GM-CSF in Patients With ALI/ARDS
Respiratory Distress Syndrome, Adult
Primary: Ventilator-free Days During Days 1-28 — 10.8; 10.7 Days
N/A N=1,705 ED Lung Protective Ventilation to Reduce Complications
Mechanical Ventilation · Ventilator-associated Conditions · ARDS
Primary: Number of Patients That Experience Pulmonary Complications After Admission From the Emergency Department — 171; 38 participants
Phase 3 N=30 Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)
SARS-CoV 2 · ARDS
Primary: Change in Arterial Blood Oxygen Content to Fraction of Inspired Oxygen Ratio (PaO2/FiO2) — 10.7; 21.4; 61.1; 11.8 mmHg
N/A N=219 Mechanical Ventilation in the Emergency Department: A Prospective Cross-Sectional Study
Respiratory Failure · Mechanical Ventilation · Acute Lung Injury
Primary: To Further Characterize ED Mechanical Ventilation — 500 mL
Phase 2 N=5 The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury
Lung Injury, Acute
Primary: Heart Rate Assessments Upto Day 7 (Part B) — 87.4; 97.7; 87.9; 95.3 Beats per minute
N/A N=524 Sigh Ventilation to Increase Ventilator-Free Days in Victims of Trauma at Risk for Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome
Primary: Ventilator-free Days (VFDs) — 18.4; 16.1 days
Phase 2 N=149 Aerosolized Surfactant in Neonatal RDS
Respiratory Distress Syndrome, Newborn
Primary: Number of Participants With Adverse Events as a Measure of Safety and Feasibility — 3; 8; 4; 12 Participants
Phase 1 N=18 Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome
Sepsis · Acute Lung Injury · Acute Respiratory Distress Syndrome
Primary: Number of Participants With Adverse Events — 3; 4; 5; 4 Participants
Phase 3 N=648 Delivery Room Management Trial of Premature Infants at High Risk of Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Primary: Death or Chronic Lung Disease — 76; 68; 62 participants
N/A N=39 ABCA3 Gene and RDS in Late Preterm and Term Infants
Respiratory Distress Syndrome, Newborn
Primary: Mortality — 5; 3; 5 Participants
Phase 2 N=72 A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
COVID · Covid-19 · Coronavirus
Primary: Number of Subjects Who Experienced Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs — 4; 23; 22; 1 Participants
Phase 2 N=33 Hemodynamics and Extravascular Lung Water in Acute Lung Injury
Acute Lung Injury
Primary: The Primary Efficacy Variable Will be the Total Reduction in Measured Lung Water
Phase 4 N=31 Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection
SARS-CoV Infection
Primary: Mechanical Ventilation — 1; 1 Participants
N/A N=16 Electrical Impedance Tomography for Optimization of Positive End-Expiratory Pressure: Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome · ARDS
Primary: Mechanical Power — 1.87; -2.50 J/min — p=.002
Phase 2 N=61 LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
Acute Respiratory Distress Syndrome (ARDS)
Primary: Change in Oxygen Saturation to Fraction of Inspired Oxygen Concentration (SpO2/FiO2) Ratio — 320; 334; 376; 336 SpO2/FiO2 Ratio — p=0.02
Phase 2 N=123 A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)
Respiratory Distress Syndrome, Newborn
Primary: Oxygen Requirement and Ventilatory Support -- SpO2/FiO2 Ratio — 3.33; 3.31; 3.36; 3.55 SpO2/FiO2 ratio — p=0.930
N/A N=120 Treatment of Critical Illness Polyneuromyopathy
Acute Respiratory Failure
Primary: The Primary Outcome Variable for This Study Will be the Short Form of the Continuous Scale Physical Functional Performance Test (CS-PFP) Called the PFP-10 — 19.0; 20.9…
Phase 2 N=448 Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)
Acute Respiratory Distress Syndrome · Coronavirus Infection
Primary: Number of Participants Who Are Classified 8 (Dead), 7 (Hospitalized, on Invasive Mechanical Ventilation or ECMO), or 6 (Hospitalized, on Non-invasive Ventilation or High…
Phase 2 N=53 Nebulised Rt-PA for ARDS Due to COVID-19
COVID
Primary: Efficacy - PaO2/FiO2 Ratio — 227; 209; 155; 248 mmHg (rounded)